Table 2.
Anticoagulant treatment and risk of 28‐day COVID‐19 mortality.
| (a) Stratified by anticoagulant type in nursing home residents | ||||||
|---|---|---|---|---|---|---|
| Exposure | Sample | Exposed, n (matched unexposed controls, n) | Deceased, n (%) | OR (95% CI) | ||
| Exposed | Unexposed | Model 1 | Model 2 | |||
| Any use of anticoagulants | All | 91 (91) | 26 (29) | 45 (49) | 0.41 (0.22–0.75) | 0.31 (0.16–0.62) |
| LMWH, incident | Including LMWH, incident users + controls | 46 (46) | 10 (22) | 21 (46) | 0.33 (0.13–0.81) | 0.29 (0.11–0.76) |
| DOAC/Warfarin,a prevalent | Including DOAC/Warfarin, prevalent users +controls | 45 (45) | 16 (36) | 24 (53) | 0.48 (0.20–1.12) | 0.35 (0.12–0.99) |
| (b) Stratified by sex and age group in nursing home residents | |||||
|---|---|---|---|---|---|
| Sample | Exposed, n (matched unexposed controls, n) | Deceased, n (%) | OR (95% CI) | ||
| Exposed | Unexposed | Model 1 | Model 2 | ||
| All | 91 (91) | 26 (29) | 45 (49) | 0.41 (0.22–0.75) | 0.31 (0.16–0.62) |
| Women | 62 (62) | 12 (19) | 25 (40) | 0.36 (0.36–0.78) | 0.28 (0.11–0.67) |
| Men | 29 (29) | 14 (48) | 20 (69) | 0.42 (0.14–1.21) | 0.39 (0.12–1.16) |
| 70–89 years | 53 (53) | 15 (28) | 25 (47) | 0.44 (0.19–0.98) | 0.37 (0.15–0.89) |
| 90–99 years | 38 (38) | 11 (29) | 20 (53) | 0.37 (0.14–0.93) | 0.22 (0.07–0.65) |
Note: The unadjusted (Model 1) and adjusted (Model 2) odds ratios were assessed using binary logistic regression. In model 2, the analysis was adjusted for age, sex, multimorbidity, and mobility. Bold values are significant p < 0.05.
Abbreviations: DOAC, direct acting oral anticoagulant; LMWH, low molecular weight heparin; OR, odds ratio.
a
Warfarin treatment (n = 4).